Table 1

Baseline demographic and disease characteristics

CharacteristicsPatients
N=32
Gender
 Female18 (56.3)
 Male14 (43.8)
Age, years
 Median (range)62 (35–77)
 <6520 (62.5)
 ≥6512 (37.5)
ECOG PS
 024 (75.0)
 18 (25.0)
Lactate dehydrogenase
 Normal21 (65.6)
 Elevated11 (34.4)
Primary site
 Head and neck17 (53.1)
 Esophagus2 (6.3)
 Vagina and cervix7 (21.9)
 Rectum*6 (18.8)
Disease stage
 Stage III10 (31.3)
 Stage IV22 (68.8)
Metastatic site
 Lymph node14 (43.8)
 Lung11 (34.4)
 Liver7 (21.9)
 Others†12 (37.5)
Gene mutation
 BRAF2/26 (7.7)
 KIT3/26 (11.5)
 NRAS8/26 (30.8)
TPS
 <120/24 (83.3)
 ≥14/24 (16.7)
TMB
 Median (range)4 (0–7.4)
 Low (<4 muts/Mb)12/25 (48.0)
 High (≥4 muts/Mb)13/25 (52.0)
Prior treatment
 Yes16 (50.0)
 No16 (50.0)
  • Values are numbers and percentages unless otherwise noted. PD-L1 expression was evaluated by 22C3 immunohistochemistry staining.

  • *Three cases were rectal above the dentate line and three were anal canal below the dentate line

  • †Other metastatic sites included: four bone, four abdominopelvic cavity, three subcutaneous soft tissue, two pleura, two stomach, two pancreas, one adrenal gland, one small intestine, one parotid gland, one kidney; there were no brain metastases.

  • ECOG PS, Eastern Cooperative Oncology Group performance status; TMB, tumor mutation burden; TPS, tumor proportion score.